Skip to Main Content
Services Talent Knowledge
Site Search
Menu

News

August 27, 2021

Jason Klimek Interviewed on Joining Barclay Damon and Cannabis Law Background for Law360 Article

Jason Klimek, co-leader of the Cannabis Team, was interviewed by Law360’s Katryna Perera  for the article “Cannabis Atty With Tax Chops Joins Barclay Damon in NY” about joining Barclay Damon’s Rochester office and his background in cannabis law.

About the cannabis law space, Jason said, “It’s one of those once-in-a-lifetime opportunities. I mean, honestly, how often do you get to be on the ground floor of an entirely new area of law . . . and to not only be on the ground floor, but to be one of the [go-to people] in such a niche area?”

New York State, which recently experienced a change in governor, will continue its efforts with the legalization of adult-use cannabis. “We’re very hopeful that it will move forward with Governor Hochul and we can start really ramping up the industry,” Jason said. “If New York wants to become a big player and be the best we can be, we need to start moving forward, and Governor Hochul seems to want to do that.”

Regarding the Cannabis Administration and Opportunity Act, a draft bill that seeks to legalize cannabis at the federal level, Jason said, “I don’t know if that will pass. I think it faces an uphill battle . . . but hopefully we can take incremental steps to at least loosen some of the federal restrictions.”

Subscribe

Click here to sign up for alerts, blog posts, and firm news.

Featured Media

Alerts

Massachusetts Federal Court Permits Sharing Clause in Protective Order in Products Liability Case

Alerts

NYS Court of Appeals Holds That Parent May Not Recover for Emotional Injuries in Prenatal-Injury Case

Alerts

Smarter Inventory Management for Pharmacies: Navigating Online Marketplace Compliance

Alerts

Emergency Wine Run, Now Legal: New York State Opens Retail-to-Retail Sales

Alerts

California's Updated Privacy Regulations: Automated Decisionmaking Technology, Cybersecurity Audits, and Risk Assessments, Part 1

Alerts

Pharmacies on High Alert: Optum Rx's 25-Percent Therapeutic-Class Cap Creates Major Legal, Operational, and Competitive Risks